A study of 60 DN patients using losartan (12.5 mg/day) plus RESV (500 mg/day) for 90 days showed that RESV could be used as a potential supplement to angiotensin receptor blockers to reduce urinary albumin excretion in patients with DN [133]. The gene discussed is ALB; the disease is liver dysplastic nodule.